Identification

Name
Niflumic Acid
Accession Number
DB04552  (EXPT02331)
Type
Small Molecule
Groups
Approved
Description

An analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis. [PubChem]

Structure
Thumb
Synonyms
  • Acide niflumique
  • Acido niflumico
  • Acidum niflumicum
  • NFA
  • Niflugel
External IDs
Lopac-N-0630 / UP 83
International/Other Brands
Niflam / Niflugel / Nifluril
Categories
UNII
4U5MP5IUD8
CAS number
4394-00-7
Weight
Average: 282.218
Monoisotopic: 282.061612157
Chemical Formula
C13H9F3N2O2
InChI Key
JZFPYUNJRRFVQU-UHFFFAOYSA-N
InChI
InChI=1S/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20)
IUPAC Name
2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid
SMILES
OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1

Pharmacology

Indication

Used in the treatment of rheumatoid arthritis.

Structured Indications
Not Available
Pharmacodynamics

Niflumic acid, a nonsteroidal anti-inflammatory fenamate, is a Ca2+-activated Cl- channel blocker.

Mechanism of action

Niflumic acid is able to inhibit both phospholipase A2 as well as COX-2, thereby acting as an antiinflamatory and pain reduction agent.

TargetActionsOrganism
APhospholipase A2
inhibitor
Human
AProstaglandin G/H synthase 2
inhibitor
Human
UChloride channel protein ClC-Ka
inducer
Human
UProstaglandin G/H synthase 1Not AvailableHuman
UCytosolic phospholipase A2Not AvailableHuman
UUDP-glucuronosyltransferase 1-9Not AvailableHuman
Absorption

Well absorbed following oral administration.

Volume of distribution
Not Available
Protein binding

90% bound to plasma proteins.

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

2.5 hours

Clearance
Not Available
Toxicity

Oral, mouse: LD50 = 350 mg/kg; Oral, rat: LD50 = 250 mg/kg

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with 5-androstenedione.Experimental, Illicit
AbciximabNiflumic Acid may increase the anticoagulant activities of Abciximab.Approved
AcebutololNiflumic Acid may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolNiflumic Acid may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Niflumic Acid.Approved, Vet Approved
AclarubicinNiflumic Acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Niflumic Acid.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Aldosterone.Experimental, Investigational
AldoxorubicinNiflumic Acid may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Alendronic acid.Approved
AliskirenNiflumic Acid may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Alminoprofen.Experimental
AlprenololNiflumic Acid may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Niflumic Acid.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Amcinonide.Approved
AmikacinNiflumic Acid may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideNiflumic Acid may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinNiflumic Acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodNiflumic Acid may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Anisodamine.Investigational
AnnamycinNiflumic Acid may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Niflumic Acid.Approved
Antithrombin III humanNiflumic Acid may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanNiflumic Acid may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Apocynin.Investigational
ApramycinNiflumic Acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Apremilast.Approved, Investigational
ArbekacinNiflumic Acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinNiflumic Acid may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanNiflumic Acid may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololNiflumic Acid may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Atamestane.Investigational
AtenololNiflumic Acid may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Niflumic Acid.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Niflumic Acid.Approved
BalsalazideNiflumic Acid may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminNiflumic Acid may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololNiflumic Acid may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinNiflumic Acid may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Niflumic Acid.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Niflumic Acid.Approved
BenorilateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Niflumic Acid.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Betamethasone.Approved, Vet Approved
BetaxololNiflumic Acid may decrease the antihypertensive activities of Betaxolol.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Niflumic Acid.Approved, Investigational
BevantololNiflumic Acid may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Niflumic Acid.Approved, Investigational
BisoprololNiflumic Acid may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinNiflumic Acid may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololNiflumic Acid may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Niflumic Acid.Approved
BucillamineThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Bucillamine.Investigational
BucindololNiflumic Acid may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Bufexamac.Experimental
BufuralolNiflumic Acid may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Bumadizone.Experimental
BumetanideNiflumic Acid may decrease the diuretic activities of Bumetanide.Approved
BupranololNiflumic Acid may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Niflumic Acid.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Niflumic Acid.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Niflumic Acid.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Niflumic Acid.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Niflumic Acid.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Niflumic Acid.Approved, Vet Approved, Withdrawn
CarteololNiflumic Acid may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolNiflumic Acid may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Niflumic Acid.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Niflumic Acid.Approved, Investigational
CeliprololNiflumic Acid may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinNiflumic Acid may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Niflumic Acid.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Niflumic Acid.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Niflumic Acid.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Niflumic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Niflumic Acid.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Niflumic Acid.Approved
CinoxacinNiflumic Acid may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidNiflumic Acid may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Niflumic Acid.Vet Approved
CloranololNiflumic Acid may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Niflumic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Niflumic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Niflumic Acid.Experimental
CyclosporineNiflumic Acid may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateNiflumic Acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinNiflumic Acid may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidNiflumic Acid may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanNiflumic Acid may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinNiflumic Acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Niflumic Acid.Experimental
DesirudinNiflumic Acid may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Niflumic Acid.Approved, Investigational
DextranNiflumic Acid may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Niflumic Acid may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Niflumic Acid may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Niflumic Acid may increase the anticoagulant activities of Dextran 75.Approved
DibekacinNiflumic Acid may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Niflumic Acid.Approved, Vet Approved
DicoumarolNiflumic Acid may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Niflumic Acid.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Niflumic Acid.Approved
DihydrostreptomycinNiflumic Acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Niflumic Acid.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Niflumic Acid.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Niflumic Acid.Approved
DoxorubicinNiflumic Acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneNiflumic Acid may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Niflumic Acid is combined with E-6201.Investigational
Edetic AcidNiflumic Acid may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanNiflumic Acid may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Niflumic Acid.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Niflumic Acid.Approved
EnoxacinNiflumic Acid may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinNiflumic Acid may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Niflumic Acid.Experimental
EpanololNiflumic Acid may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Epirizole.Approved
EpirubicinNiflumic Acid may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneNiflumic Acid may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Niflumic Acid.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Niflumic Acid.Approved
EquileninThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Equilin.Approved
EsmololNiflumic Acid may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Estrone sulfate.Approved
Etacrynic acidNiflumic Acid may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Niflumic Acid.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ethenzamide.Experimental
Ethyl biscoumacetateNiflumic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Niflumic Acid.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Niflumic Acid.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Niflumic Acid.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Niflumic Acid.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Feprazone.Experimental
Ferulic acidNiflumic Acid may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Niflumic Acid.Approved, Investigational
FleroxacinNiflumic Acid may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Niflumic Acid.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fludrocortisone.Approved
FluindioneNiflumic Acid may increase the anticoagulant activities of Fluindione.Investigational
FlumequineNiflumic Acid may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Niflumic Acid.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Niflumic Acid.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Niflumic Acid.Approved, Nutraceutical, Vet Approved
FondaparinuxNiflumic Acid may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumNiflumic Acid may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Niflumic Acid.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Niflumic Acid.Approved
FramycetinNiflumic Acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideNiflumic Acid may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateNiflumic Acid may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinNiflumic Acid may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinNiflumic Acid may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Niflumic Acid.Approved, Withdrawn
GemifloxacinNiflumic Acid may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinNiflumic Acid may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinNiflumic Acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ANiflumic Acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Niflumic Acid may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinNiflumic Acid may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Niflumic Acid is combined with HE3286.Investigational
HeparinNiflumic Acid may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Higenamine.Investigational
HydralazineNiflumic Acid may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Niflumic Acid.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Niflumic Acid.Approved, Investigational
Hygromycin BNiflumic Acid may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Niflumic Acid.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Icatibant.Approved
IdarubicinNiflumic Acid may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxNiflumic Acid may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Niflumic Acid.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Niflumic Acid.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Niflumic Acid.Approved
IndenololNiflumic Acid may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Niflumic Acid.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Indoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Niflumic Acid.Approved, Investigational
IsepamicinNiflumic Acid may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Istaroxime.Investigational
KanamycinNiflumic Acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Niflumic Acid.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Niflumic Acid.Approved
LabetalolNiflumic Acid may decrease the antihypertensive activities of Labetalol.Approved
LandiololNiflumic Acid may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Niflumic Acid.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Niflumic Acid.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Niflumic Acid.Approved, Investigational
LepirudinNiflumic Acid may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanNiflumic Acid may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololNiflumic Acid may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinNiflumic Acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Niflumic Acid.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Niflumic Acid.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Niflumic Acid.Approved
LonazolacThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Niflumic Acid.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Niflumic Acid.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Niflumic Acid.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Niflumic Acid.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Niflumic Acid.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Niflumic Acid.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Niflumic Acid is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Niflumic Acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Niflumic Acid.Approved
MelagatranNiflumic Acid may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Niflumic Acid.Approved, Vet Approved
MepindololNiflumic Acid may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineNiflumic Acid may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Metamizole.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Niflumic Acid.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Niflumic Acid.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Methylprednisolone.Approved, Vet Approved
MetipranololNiflumic Acid may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Niflumic Acid.Approved
MetoprololNiflumic Acid may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideNiflumic Acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinNiflumic Acid may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Niflumic Acid.Approved
MizoribineThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Niflumic Acid.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Niflumic Acid.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Niflumic Acid.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Niflumic Acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Niflumic Acid.Approved
NadololNiflumic Acid may decrease the antihypertensive activities of Nadolol.Approved
NadroparinNiflumic Acid may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNiflumic Acid may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Niflumic Acid.Approved
Nalidixic AcidNiflumic Acid may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Niflumic Acid.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Niflumic Acid is combined with NCX 1022.Investigational
NeamineNiflumic Acid may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololNiflumic Acid may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinNiflumic Acid may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinNiflumic Acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Niflumic Acid.Approved
NetilmicinNiflumic Acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nifenazone.Experimental
NimesulideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nitroaspirin.Investigational
NorfloxacinNiflumic Acid may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Niflumic Acid.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Niflumic Acid.Approved
OlsalazineNiflumic Acid may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of can be d when Niflumic Acid is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Niflumic Acid.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Orgotein.Vet Approved
OtamixabanNiflumic Acid may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Niflumic Acid.Approved
Oxolinic acidNiflumic Acid may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololNiflumic Acid may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Niflumic Acid.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Parecoxib.Approved
ParomomycinNiflumic Acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Parthenolide.Investigational
PazufloxacinNiflumic Acid may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinNiflumic Acid may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololNiflumic Acid may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateNiflumic Acid may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateNiflumic Acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Niflumic Acid.Approved
PhenindioneNiflumic Acid may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonNiflumic Acid may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Niflumic Acid.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Niflumic Acid.Approved, Investigational
PindololNiflumic Acid may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidNiflumic Acid may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinNiflumic Acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideNiflumic Acid may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pirfenidone.Approved, Investigational
Piromidic acidNiflumic Acid may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Niflumic Acid.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pirprofen.Experimental
Platelet Activating FactorNiflumic Acid may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinNiflumic Acid may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinNiflumic Acid may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Niflumic Acid.Approved
PractololNiflumic Acid may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Niflumic Acid.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Niflumic Acid can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Propacetamol.Approved, Investigational
PropranololNiflumic Acid may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Niflumic Acid.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Niflumic Acid.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Niflumic Acid.Vet Approved
Protein CNiflumic Acid may increase the anticoagulant activities of Protein C.Approved
Protein S humanNiflumic Acid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeNiflumic Acid may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinNiflumic Acid may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Niflumic Acid is combined with PTC299.Investigational
PuromycinNiflumic Acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Niflumic Acid.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Niflumic Acid.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Niflumic Acid.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Niflumic Acid.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Niflumic Acid.Approved, Experimental, Investigational
ReviparinNiflumic Acid may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinNiflumic Acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Risedronate.Approved, Investigational
RivaroxabanNiflumic Acid may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Niflumic Acid.Investigational, Withdrawn
RosoxacinNiflumic Acid may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinNiflumic Acid may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinNiflumic Acid may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Niflumic Acid.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Niflumic Acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Niflumic Acid.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Niflumic Acid.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Niflumic Acid.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Niflumic Acid.Approved
SemapimodThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Serrapeptase.Investigational
SisomicinNiflumic Acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinNiflumic Acid may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Niflumic Acid.Approved
SotalolNiflumic Acid may decrease the antihypertensive activities of Sotalol.Approved
SP1049CNiflumic Acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinNiflumic Acid may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinNiflumic Acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Niflumic Acid.Approved
SRT501The risk or severity of adverse effects can be increased when Niflumic Acid is combined with SRT501.Investigational
StreptomycinNiflumic Acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinNiflumic Acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Niflumic Acid.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Niflumic Acid.Approved
SulodexideNiflumic Acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Niflumic Acid.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Niflumic Acid.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Suxibuzone.Experimental
TacrolimusNiflumic Acid may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Niflumic Acid.Approved
TalinololNiflumic Acid may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Niflumic Acid.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Niflumic Acid.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Niflumic Acid.Approved, Investigational
TemafloxacinNiflumic Acid may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Niflumic Acid.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Niflumic Acid.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Teriflunomide.Approved
TertatololNiflumic Acid may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Niflumic Acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololNiflumic Acid may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tixocortol.Approved, Withdrawn
TobramycinNiflumic Acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Niflumic Acid.Approved
TorasemideNiflumic Acid may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Niflumic Acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Niflumic Acid.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Niflumic Acid.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Triamcinolone.Approved, Vet Approved
TriamtereneNiflumic Acid may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Niflumic Acid.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Triptolide.Investigational
TrovafloxacinNiflumic Acid may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinNiflumic Acid may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Niflumic Acid.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Niflumic Acid.Investigational, Withdrawn
ValrubicinNiflumic Acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Niflumic Acid.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Niflumic Acid.Approved
WarfarinNiflumic Acid may increase the anticoagulant activities of Warfarin.Approved
XimelagatranNiflumic Acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Niflumic Acid.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Niflumic Acid.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinNiflumic Acid may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinNiflumic Acid may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
  1. Criddle DN, de Moura RS, Greenwood IA, Large WA: Inhibitory action of niflumic acid on noradrenaline- and 5-hydroxytryptamine-induced pressor responses in the isolated mesenteric vascular bed of the rat. Br J Pharmacol. 1997 Mar;120(5):813-8. [PubMed:9138686]
External Links
Human Metabolome Database
HMDB15573
KEGG Compound
C13698
PubChem Compound
4488
PubChem Substance
46504657
ChemSpider
4333
BindingDB
85507
ChEBI
34888
ChEMBL
CHEMBL63323
Therapeutic Targets Database
DAP000972
PharmGKB
PA164746749
IUPHAR
2439
Guide to Pharmacology
GtP Drug Page
HET
NFL
ATC Codes
M02AA17 — Niflumic acidM01AX02 — Niflumic acid
PDB Entries
1td7 / 2wm3
MSDS
Download (73.3 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)203 °CNot Available
water solubility19 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.43TAKACS-NOVAK,K ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0883 mg/mLALOGPS
logP4.33ALOGPS
logP3.12ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)1.88ChemAxon
pKa (Strongest Basic)5.51ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.22 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity65.93 m3·mol-1ChemAxon
Polarizability24.21 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9298
Blood Brain Barrier+0.9115
Caco-2 permeable+0.5318
P-glycoprotein substrateNon-substrate0.7803
P-glycoprotein inhibitor INon-inhibitor0.8783
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.9236
CYP450 2C9 substrateNon-substrate0.7654
CYP450 2D6 substrateNon-substrate0.8881
CYP450 3A4 substrateNon-substrate0.776
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.7762
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7812
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8322
BiodegradationNot ready biodegradable0.992
Rat acute toxicity3.0838 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.988
hERG inhibition (predictor II)Non-inhibitor0.7993
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.79 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001r-0090000000-d212523eaa8e47f9054f
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-0090000000-7f1bc979a7f8c7077a95
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-0090000000-dd0310ff257f2921383c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-0490000000-b0e41ea5dbccc5a0b0f6
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004r-1980000000-1096f092d7eef8500782
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-2930000000-038c8f35115d57e400ee
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004l-4900000000-c2e52373f3300219b388
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0g6u-9700000000-a47c140f0903976ebc7f
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00dj-9200000000-4a59d785457835ab936e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0090000000-1d2a69ae63d48722b5c1
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0190000000-30b3c58f88b7803349dd
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014j-0960000000-b837ec0e3f19a1b86316
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0090000000-065361d6324d9eb6997f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00lr-0090000000-339e0764e241daa8de0a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0090000000-72bb52f92fc53b179b00
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0190000000-7e1966497ac2f37804a2
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00kb-0690000000-30e96da9f66c54d2cea7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00kb-1930000000-0b215b890ef639ace9db
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00vm-2900000000-7889ec00129ecfe21759
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-8900000000-bdc72e63ea5feea2f90d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-9400000000-03798ba57e12a1f6bf35
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0159-0090000000-429b0738786cba43f8d7
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014j-2690000000-7b7c343f3f0b113fd715

Taxonomy

Description
This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Trifluoromethylbenzenes
Direct Parent
Trifluoromethylbenzenes
Alternative Parents
Pyridinecarboxylic acids / Aniline and substituted anilines / Aminopyridines and derivatives / Imidolactams / Vinylogous amides / Heteroaromatic compounds / Amino acids / Secondary amines / Azacyclic compounds / Carboxylic acids
show 7 more
Substituents
Trifluoromethylbenzene / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Aniline or substituted anilines / Aminopyridine / Pyridine / Imidolactam / Vinylogous amide / Heteroaromatic compound / Amino acid or derivatives
show 20 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
pyridines, aromatic carboxylic acid (CHEBI:34888)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Receptor binding
Specific Function
PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides, this releases glycerophospholipids and arachidonic acid that serve as the precursors of signal molecules.
Gene Name
PLA2G1B
Uniprot ID
P04054
Uniprot Name
Phospholipase A2
Molecular Weight
16359.535 Da
References
  1. Jabeen T, Singh N, Singh RK, Sharma S, Somvanshi RK, Dey S, Singh TP: Non-steroidal anti-inflammatory drugs as potent inhibitors of phospholipase A2: structure of the complex of phospholipase A2 with niflumic acid at 2.5 Angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1579-86. Epub 2005 Nov 19. [PubMed:16301791]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Jabeen T, Singh N, Singh RK, Sharma S, Somvanshi RK, Dey S, Singh TP: Non-steroidal anti-inflammatory drugs as potent inhibitors of phospholipase A2: structure of the complex of phospholipase A2 with niflumic acid at 2.5 Angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1579-86. Epub 2005 Nov 19. [PubMed:16301791]
  2. Diao HL, Zhu H, Ma H, Tan HN, Cong J, Su RW, Yang ZM: Rat ovulation, implantation and decidualization are severely compromised by COX-2 inhibitors. Front Biosci. 2007 May 1;12:3333-42. [PubMed:17485303]
  3. Alpert E, Gruzman A, Tennenbaum T, Sasson S: Selective cyclooxygenase-2 inhibitors stimulate glucose transport in L6 myotubes in a protein kinase Cdelta-dependent manner. Biochem Pharmacol. 2007 Feb 1;73(3):368-77. Epub 2006 Oct 13. [PubMed:17098211]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Voltage-gated chloride channel activity
Specific Function
Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport...
Gene Name
CLCNKA
Uniprot ID
P51800
Uniprot Name
Chloride channel protein ClC-Ka
Molecular Weight
75284.08 Da
References
  1. Picollo A, Liantonio A, Babini E, Camerino DC, Pusch M: Mechanism of interaction of niflumic acid with heterologously expressed kidney CLC-K chloride channels. J Membr Biol. 2007 Apr;216(2-3):73-82. Epub 2007 Jul 21. [PubMed:17659402]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Talbot S, Lin JC, Lahjouji K, Roy JP, Senecal J, Morin A, Couture R: Cigarette smoke-induced kinin B1 receptor promotes NADPH oxidase activity in cultured human alveolar epithelial cells. Peptides. 2011 Jul;32(7):1447-56. doi: 10.1016/j.peptides.2011.05.005. Epub 2011 May 11. [PubMed:21600945]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Phospholipase a2 activity
Specific Function
Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory...
Gene Name
PLA2G4A
Uniprot ID
P47712
Uniprot Name
Cytosolic phospholipase A2
Molecular Weight
85238.2 Da
References
  1. Jabeen T, Singh N, Singh RK, Sharma S, Somvanshi RK, Dey S, Singh TP: Non-steroidal anti-inflammatory drugs as potent inhibitors of phospholipase A2: structure of the complex of phospholipase A2 with niflumic acid at 2.5 Angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1579-86. Epub 2005 Nov 19. [PubMed:16301791]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Mano Y, Usui T, Kamimura H: In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid. Biopharm Drug Dispos. 2006 Jan;27(1):1-6. [PubMed:16278927]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucin...
Gene Name
SLC16A7
Uniprot ID
O60669
Uniprot Name
Monocarboxylate transporter 2
Molecular Weight
52199.745 Da
References
  1. Broer S, Broer A, Schneider HP, Stegen C, Halestrap AP, Deitmer JW: Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J. 1999 Aug 1;341 ( Pt 3):529-35. [PubMed:10417314]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucin...
Gene Name
SLC16A1
Uniprot ID
P53985
Uniprot Name
Monocarboxylate transporter 1
Molecular Weight
53943.685 Da
References
  1. Broer S, Broer A, Schneider HP, Stegen C, Halestrap AP, Deitmer JW: Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J. 1999 Aug 1;341 ( Pt 3):529-35. [PubMed:10417314]

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 03:43